DDInter178 DDInter737
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657]
Fingolimod {u} (Compound) treats {v} (Disease) multiple sclerosis
Fingolimod {u} (Compound) binds {v} (Gene) S1PR4
Fingolimod {u} (Compound) is included by {v} (Pharmacologic Class) Sphingosine 1-Phosphate Receptor Modulators
Fingolimod {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Fingolimod {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olanzapine
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Fingolimod (Compound) treats multiple sclerosis (Disease)
Fingolimod (Compound) binds S1PR4 (Gene)
Fingolimod (Compound) is included by Sphingosine 1-Phosphate Receptor Modulators (Pharmacologic Class)
Fingolimod (Compound) causes Cardiac arrest (Side Effect)
Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine
Fingolimod may lead to a major life threatening interaction when taken with Tizanidine
Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib